Jemperli plus chemotherapy demonstrated superior overall survival ... Keytruda group. A first-line treatment combination of ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

However, while overall survival (OS) was numerically greater in the pembrolizumab group, that improvement did not reach ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer ... the Keytruda-pemetrexed-platinum chemotherapy combination significantly improved overall survival ...

The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant pembrolizumab demonstrated significant overall-survival improvement in patients with ...

Around a quarter of untreated lung cancer patients in England are ... NICE says current evidence suggests Keytruda can extend overall survival by around three months on average, but says a more ...